|Podcasts|August 10, 2020

Speaking of Urology: What patients undergoing HIFU should expect postoperatively

In this episode, Samuel J. Peretsman, MD, explains what he tells patients undergoing HIFU to expect postoperatively.

Catch up on "Speaking of Urology":

A HIFU expert discusses his treatment criteria

Dr. Angela Smith discusses Jelmyto for low-grade UTUC

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe

Related Content

FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC

ByHannah Clarke

July 31st 2026

Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice

ByJoshua Lang, MD, MS

July 31st 2026

Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer

ByHannah Clarke

July 30th 2026

Pearls & Perspectives: From Prostate Cancer Diagnosis to Patient Advocacy, with Gabe Canales

ByAmy M. Pearlman, MD,Larry Lipshultz, MD,Gabe Canales

July 29th 2026

Prostate Cancer Working Group 4: What urologists need to know

ByHannah Clarke

July 28th 2026

Latest CME

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Speaking of Urology: What patients undergoing HIFU should expect postoperatively

Related Content

FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC

Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice

Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer

Pearls & Perspectives: From Prostate Cancer Diagnosis to Patient Advocacy, with Gabe Canales

Prostate Cancer Working Group 4: What urologists need to know

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Radioligand Therapy 101: The Science Behind the Strategy

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Trending on Urology Times

FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC

Testosterone deficiency: FAQs from the AUA guideline

Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice

Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer

From hype to practice: Urologists assess AI's real impact